# Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

> **NCT02591030** · PHASE2,PHASE3 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 191 (actual)

## Conditions studied

- Bile Duct Cancer

## Interventions

- **DRUG:** GEMCIS
- **DRUG:** mFolfirinox

## Key facts

- **NCT ID:** NCT02591030
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2018-06-27
- **Final completion:** 2020-01-16
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2022-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591030, "Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02591030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*